IBIO iBio, Inc.
Financings ·
The AI-driven antibody company sold shares and pre-funded warrants at $2.35 in a private placement. It says the cash runs into calendar 2028 and that first human trials of IBIO-610 start in early 2027.
The company has until January 26, 2026 to regain compliance. Its shares keep trading on The Nasdaq Capital Market under the symbol IBIO for now.
The company says it is withdrawing its listing voluntarily and has complied with the exchange's rules for doing so.
iBio sold 240,807 common shares at $2.72 each to its directors and officers, for about $655,000 in gross proceeds, and the placement closed on January 10, 2025. The company says the price was at-the-market.
iBio agreed to license an anti-myostatin antibody from AstralBio and paid the $750,000 upfront fee in common stock. AstralBio can earn up to $28 million in milestones, and the antibody's data so far are preclinical.
iBio is a clinical-stage biotechnology company that uses artificial intelligence and machine learning to develop hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases. The company is focused on the quality, durability and tolerability of weight loss, including preserving muscle mass, compared with current GLP-1 receptor agonist therapies. The first molecule from its AI Drug Discovery Platform to enter clinical development, IBIO-600, a long-acting myostatin antibody, has a Phase 1 trial in Australia, where the first participant was dosed in June 2026. The company reports that 31 participants have been dosed across the first four cohorts. IBIO-610, a long-acting Activin E antibody, is in IND-enabling studies, with first-in-human trials anticipated in the first half of calendar year 2027. IBIO-800, a myostatin and Activin A bispecific antibody, is in IND-enabling development for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). On August 27, 2026, the company entered into an exclusive worldwide license with AstralBio for an amylin program.
| Product or program | What it is | Stage |
|---|---|---|
| IBIO-600 | Long-acting myostatin antibody for obesity | Phase 1 in Australia; first participant dosed June 2026 |
| IBIO-610 | Long-acting Activin E antibody for obesity | IND-enabling studies; first-in-human trials expected in the first half of calendar year 2027 |
| IBIO-800 | Myostatin and Activin A bispecific antibody for PH-HFpEF | IND-enabling development |
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Research and development | $19.6 million | $8.3 million |
| Net income (loss) | -$33.0 million | -$18.4 million |
| Cash from operations | -$23.2 million | -$15.3 million |
| Cash and equivalents | $56.4 million | $8.6 million |
| Short-term investments | $31.6 million | $0 |
Our latest story on this, dated Mar 3, 2025: "iBio files Form 25 to withdraw its common stock from NYSE American". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 9, 2026: "iBio raises $26 million from Frazier-led investors to push obesity antibodies toward clinic". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 1, 2025: "iBio receives Nasdaq notice for trading below $1.00 minimum bid price". The story links the filing or release it is based on. Read the story.
iBio, Inc. trades under the ticker IBIO on NASDAQ.
iBio, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0JV0.
The SEC Central Index Key (CIK) for iBio, Inc. is 1420720. Its filings are on SEC EDGAR.
64,307,256 shares as of 2026-08-27, per the cover page of its 10-K filed 2026-08-28.
Our directory records iBio, Inc. under United States.
Our directory classifies iBio, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for iBio, Inc. is US4510337086.
aibio.space lists iBio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
iBio is a clinical-stage biotechnology company that uses artificial intelligence and machine learning to develop hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases. The company is focused on the quality, durability and tolerability of weight loss, including preserving muscle mass, compared with current GLP-1 receptor agonist therapies.
IBIO-600: Long-acting myostatin antibody for obesity Stage: Phase 1 in Australia; first participant dosed June 2026.
IBIO-610: Long-acting Activin E antibody for obesity Stage: IND-enabling studies; first-in-human trials expected in the first half of calendar year 2027.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Reported a financing. SEC Form S-3. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed to remove its shares from exchange listing. SEC Form 25. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio